TC
AXSM icon

TAP Consulting’s Axsome Therapeutics AXSM Stock Holding History

TAP Consulting’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-38,429
Closed -$1.59M – 121
2022
Q1 		$1.59M Buy
+38,429
New +$1.19M 0.42% 55

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

TAP Consulting's AXSM Position: Q2 2022 in Review

TAP Consulting sold out of Axsome Therapeutics (AXSM) in Q2 2022, closing a stake of 38,429 shares — an estimated $1.59M sold.

TAP Consulting first reported a position in AXSM in Q1 2022 and held it in 1 quarter. The position peaked at $1.59M in Q1 2022. 174 funds tracked by Wall St. Rank hold AXSM as of Q2 2022.

  • TAP Consulting reported no remaining Axsome Therapeutics position as of Q2 2022 after selling out during the quarter.
  • TAP Consulting sold 38,429 Axsome Therapeutics shares in Q2 2022, an estimated $1.59M.
  • TAP Consulting first reported a position in Axsome Therapeutics in Q1 2022 and held it in 1 quarter.
  • TAP Consulting's Axsome Therapeutics position peaked at $1.59M in Q1 2022.
  • 174 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2022.

Based on TAP Consulting's 13F filing for Q2 2022, filed 26 Jul 2022.